PDCD1 and melanoma: Moreover, another study identified that the inhibition of RANKL augmented the antimetastatic efficacy of anti-PD-1/PD-L1 monoclonal antibodies (MoABs) and enhanced growth suppression in the prostate, colorectal cancer and melanoma cell lines in mouse models [86].